Thu, Jul 24, 2014, 5:06 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

justarook04 286 posts  |  Last Activity: 3 hours ago Member since: Apr 13, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • justarook04 justarook04 Jun 13, 2014 10:29 AM Flag

    I understand that but when NASDAQ prints green, Insmed still stays deep red and rarely recovers to a reasonable PPS. I see this in some BIOs lately which probably indicates the "valuation" with no revenues etc. allows and PPS the MMs want to make. Used to be looming positive (yes I actually said positive) news would push the PPS higher (thinking mid $14's) but.....until we hear from the FDA or other news.

    Sentiment: Buy

  • NASDAQ has been slaughtered these past few days and Insmed has been driven down with it. This never makes any sense to me as there is nothing substantiating the suppression.

    Sentiment: Buy

  • Reply to

    who is this loser donutsforbreakfast???

    by djcalvin408 Jun 11, 2014 6:47 PM
    justarook04 justarook04 Jun 12, 2014 7:42 AM Flag

    He created himself on Yahoo March 26th 2014. Do not understand why he would be shorting at these levels. Put him on ignore.

    Sentiment: Buy

  • Lurking possibly?

    Sentiment: Buy

  • justarook04 justarook04 Jun 11, 2014 6:18 PM Flag

    other board - thx

    Sentiment: Buy

  • justarook04 justarook04 Jun 11, 2014 6:06 PM Flag

    This could also explain the shelf offering (mainly form 4's) from last week. June has not been good to us here at Insmed....this year it changes??

    Sentiment: Buy

  • Reply to

    NEWEST Short Interest.....

    by insmhistorian Jun 10, 2014 4:24 PM
    justarook04 justarook04 Jun 11, 2014 1:24 PM Flag

    One of mine was Eastern Airlines - got lucky made $1000 before it went bankrupt (if I remember correctly). I always had the stock certificates - early 80's for me

    Sentiment: Buy

  • Reply to

    NEWEST Short Interest.....

    by insmhistorian Jun 10, 2014 4:24 PM
    justarook04 justarook04 Jun 11, 2014 11:22 AM Flag

    Tom, in the end it should be about FAIR valuation based on formulas/multipliers and whatever else is reasonably FAIR. IDIX was valued under $1B until last Friday when the stock went into the $7 range. IDIX has had many failures over the past 4 years (let's call these "set backs"). The analysts had a $5.80 or so consensus PT. Yet, MRK (and possibly others) valued IDIX at $3.85B or $24/shr. For what? Point here is Insmed has shown the last 3 months some very positive results in their trials. Analysts has a consensus $33+ PT. But the market has this PPS just over $13. Does not compute in my book but I am just a small time investor.

    Sentiment: Buy

  • Reply to

    analyst opinion

    by iounothjing1 Jun 10, 2014 7:41 AM
    justarook04 justarook04 Jun 10, 2014 3:42 PM Flag

    No, added up the PTs and one of the $30 is missing (to come up with what Yahoo's average now is: $33.40 It is NOT Piper Jaffray, UBS and JMP Securities. The $30 PT's are Canaccord, HC Wainwright or Leerink Swann. IR has not responded

    Sentiment: Buy

  • Reply to

    analyst opinion

    by iounothjing1 Jun 10, 2014 7:41 AM
    justarook04 justarook04 Jun 10, 2014 10:39 AM Flag

    IOU, One of the Analysts that have a PT of $30 looks to have been removed. I have asked IR but no response.

    Sentiment: Buy

  • This board is becoming useless

    Sentiment: Buy

  • Reply to

    JMP securities and IDIX (and INSM)

    by justarook04 Jun 9, 2014 3:21 PM
    justarook04 justarook04 Jun 9, 2014 4:17 PM Flag

    Historian, as FUD has documented, after seeing this "buyout", WHAT does that mean Insmed is worth? How could the market so UNDERVALUE IDIX? Here we sit at $12.91 and we are viewed as a "failed primary PH II" company. NTM has no approved treatment and is only getting to be a more prolific disease. At least IDIX has $205M cash on hand LOL

    Sentiment: Buy

  • Reply to

    JMP securities and IDIX (and INSM)

    by justarook04 Jun 9, 2014 3:21 PM
    justarook04 justarook04 Jun 9, 2014 3:52 PM Flag

    for IDIX? Here are some tidbits (probably tainted but still):

    "based on the data and facts we have in front of us right now, this might be one of the worst deals I've ever seen. Now understand that Idenix could deliver on samatasvir, its NS5A inhibitor, or its two other nucleotide prodrugs (IDX21437 and IDX21459), which would make this deal very much worth Merck's while. However, historically speaking, Idenix has one of the worst track records among all biotechs.

    In 2010, Idenix had its then-lead compounds IDX184 and IDX320 placed on clinical hold by the Food and Drug Administration. Following this hold IDX184 continued on while IDX320 wound up be discontinued. In 2012, IDX184 was placed on clinical hold a second time along with IDX19368 following the death of a patient in Bristol-Myers Squibb's (NYSE: BMY ) study involving BMS-986094 (the drug it acquired when it bought Inhibitex). Because Idenix's investigational drugs worked along the same pathway as Bristol's, the FDA decided to exercise caution. Long story short, both IDX184 and IDX19368 would be scrapped shortly thereafter. Finally, last year the FDA placed a clinical hold on IDX20963 until it delivered preclinical safety data to the regulatory agency. That's four clinical holds in four years folks (or five if you count IDX184 twice), aptly giving it the name of the "most unlucky biotech in the world" according to Foolish biotech specialist Brian Orelli."

    Sentiment: Buy

  • JMP had IDIX at a PT of $3 as of 1/30/14. They have a $25 PT for INSM (unless something changed last week). Merck values IDIX at $24/shr. What is WRONG with this picture? IDIX just went over $7/shr last Friday after languishing in the $6's. So, the market says IDIX was only worth $1.1B and Merck says $3.85B (or thereabouts). Miffed as usual.

    Sentiment: Buy

  • Reply to

    IDIX

    by brunswicknc Jun 9, 2014 7:36 AM
    justarook04 justarook04 Jun 9, 2014 2:44 PM Flag

    The fact is IDIX was at $7.23 ($100M+ market cap) on Friday. Analysts had its PT at $5.80 and a few had a strong Sell on the stock. Yet, Merck thought $24/shr was a good deal. What this tells me is the "market" has many Biotechs (like IDIX, ECYT etc.) undervalued after the slaughter these past few months. For ECYT to be trading at $24/shr it would only have a $1B market cap.

    Sentiment: Buy

  • Reply to

    $13 in our crosshairs (again)

    by justarook04 Jun 9, 2014 9:51 AM
    justarook04 justarook04 Jun 9, 2014 2:05 PM Flag

    Kinkey,
    So you think Merck paid too much for Idenix since it was valued by the market at $7.25 (or so) and a $1.1M market cap? The Analysts set a one year PT of $5.80, which it had already exceeded. I think the market undervalued that company and has done "harm" to others with an even better potential. Unless you believe Merck is just plain Stupid!

    Sentiment: Buy

  • climbing out of the basement..........

    Sentiment: Buy

  • Reply to

    IDIX

    by brunswicknc Jun 9, 2014 7:36 AM
    justarook04 justarook04 Jun 9, 2014 8:29 AM Flag

    If they offered $1B, they would get back over $200K in cash and eliminate any further incentive payments so you would think this would be obvious. They can own Everything for almost no cost in the end. Don't forget the carried over losses that would minimize taxes on revenue for some time.

    Sentiment: Buy

  • Reply to

    License to steal

    by kinkey_boots Jun 5, 2014 8:36 AM
    justarook04 justarook04 Jun 6, 2014 3:13 PM Flag

    You know Kinkey, those options @ 12.48 issued a few days ago may have set the bottom PPS here because IF they felt the PPS would go down further - why not wait???? So far - so good

    Sentiment: Buy

  • On May 18-20, Insmed provided more positive supporting data on both NTM and CF yet the PPS is $12.26:

    May 14, 2014 15.16 15.80 14.78 14.83 457,400 14.83
    May 13, 2014 15.61 15.91 14.92 15.26 543,700 15.26
    May 12, 2014 14.49 15.85 14.47 15.73 809,200 15.73
    May 09, 2014 13.75 14.53 13.19 14.46 474,500 14.46 (see below's PR)
    May 08, 2014 13.78 15.32 13.68 13.71 927,800 13.71

    Insmed Incorporated (INSM)
    May 09, 2014

    Chief Pulse Comment by William H Lewis

    MONMOUTH JUNCTION, NJ ( Marketwired , May 08, 2014) , Insmed Incorporated ( NASDAQ: INSM ) today reported financial results for the three months ended March 31, 2014. Highlights of the first quarter of 2014 and recent weeks include: Announced top line clinical results from a phase 2 clinical study of ARIKAYCE™, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial ( NTM) lung infections;
    Applied for Breakthrough Therapy Designation in the United States for ARIKAYCE to treat NTM lung infections; Reported positive interim data from the two year, open label extension study of ARIKAYCE to treat Pseudomonas aeruginosa infections in cystic fibrosis ( CF) patients, which demonstrated long term safety and durability of effect at 12 months;
    Entered into a contract manufacturing agreement with Therapure Biopharma Inc for the manufacture of ARIKAYCE; and Received Orphan Medical Product Designation in the European Union for ARIKAYCE to treat lung infections caused by NTM. "We remain on track to discuss our recent clinical results with the U. S. Food and Drug Administration and the European Medicines Agency to determine next steps for ARIKAYCE," said Will Lewis, President and Chief Executive Officer of Insmed.
    "We look forward to the presentations of ARIKAYCE data at the American Thoracic Society's Annual Meeting later this month. The presentation of the NTM data will include data from the three month, open label portion of the study."

    Sentiment: Buy

INSM
17.61-0.51(-2.81%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.